Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 8K | 0 | 0 | 0 | 0 |
| Gross Profit | 7K | -977 | -9K | 0 | 0 |
| Operating Income | -258K | -117K | -94K | -128K | -668K |
| EBITDA | -256K | -116K | -18K | 30K | -55K |
| Net Income | -274K | -120K | -83K | -98K | -723K |
| EPS (Diluted) | — | — | — | — | — |
Financial Services
Live Price
Offline$0.02
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tanke Biosciences Corporation (TNBI) is a Financial Services stock with listed on OTC. The stock last traded around $0.02 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -129.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -129.8%, free cash flow -6.0% with operating margin -3038.1% and ROIC 99.0%. Valuation already assumes a fairly strong business story at price/sales 100.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TNBI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TNBI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TNBI Max Drawdown
-66.67%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TNBI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$723.0K
-636.6% YoY
Free Cash Flow
-$2.5M
-71334.1% YoY
Revenue Growth
+0.0%
EPS Growth
-129.8%
Gross Margin
81.4%
Net Margin
-3254.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 8K | 0 | 0 | 0 | 0 |
| Gross Profit | 7K | -977 | -9K | 0 | 0 |
| Operating Income | -258K | -117K | -94K | -128K | -668K |
| EBITDA | -256K | -116K | -18K | 30K | -55K |
| Net Income | -274K | -120K | -83K | -98K | -723K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6K | 0 | 3K | 7K | 41K |
| Total Assets | 74K | 66K | 69K | 7K | 41K |
| Total Liabilities | 0 | 249K | 165K | 95K | 101K |
| Shareholder Equity | -399K | -183K | -96K | -88K | -60K |
| Total Debt | 140K | 140K | 140K | 53K | 2K |
| Net Debt | 134K | 140K | 137K | 46K | -40K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
-33443.8% YoY
Capital Expenditures
1M
Free Cash Flow
3M
-71334.1% YoY
Key ratios
Gross Margin
81.4%
Operating Margin
-3038.1%
Net Margin
-3254.6%
ROE
86.0%
Debt / Equity
-0.35x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.